Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
Di | Lobe Sciences Ltd (2): Lobe Sciences appoints Yao as CFO, EVP | 2 | Stockwatch | ||
Di | Lobe Sciences Ltd.: Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth | 201 | ACCESS Newswire | Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr.... ► Artikel lesen | |
14.04. | Lobe Sciences Ltd (2): Lobe's Cynaptec arranges $6M (U.S.) private placement | 1 | Stockwatch | ||
14.04. | Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin | 156 | ACCESS Newswire | Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical... ► Artikel lesen | |
05.04. | Lobe Sciences Ltd (2): Lobe Sciences issues notes, shares, RSUs | 2 | Stockwatch | ||
05.04. | Lobe Sciences Ltd.: Lobe Sciences Provides Corporate Update | 525 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONXT SOLUTIONS | 0,369 | +3,36 % | Unterbewertete Healthcare Titel - BioNxt Solutions, Evotec, Novo Nordisk | Wie der Einkaufsmanager-Index in der Euro-Zone zeigt, erholt sich die Stimmung in der Industrie von Südeuropa langsam. Schlusslicht bleibt dabei die Zuversicht der Geschäftsführer der größten deutschen... ► Artikel lesen | |
AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
ATAI LIFE SCIENCES | 2,141 | +1,04 % | Atai Life Sciences: Big Deal | Fast genau vier Jahre nach dem Börsenstart am 18. Juni 2021 gibt es signifikante Veränderungen bei Atai Life Science: So schließt sich das auf die Behandlung psychischer Erkrankungen spezialisierte... ► Artikel lesen | |
SOL GLOBAL INVESTMENTS | 0,053 | -0,76 % | SOL Global Investments Corp.: SOL Global Appoints Davide Marcotti as Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 3, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
ENTHEON BIOMEDICAL CORP | 0,050 | -17,36 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - April 4, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Harrison Newlands... ► Artikel lesen | |
REVIVE THERAPEUTICS | 0,018 | +140,00 % | Revive Therapeutics Ltd: Revive develops new bucillamine formulation | ||
CYBIN | 7,900 | +0,64 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors | Burlington, Ontario--(Newsfile Corp. - June 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated May 10, 2025, it has... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales |